These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 32125403)

  • 1. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
    Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
    JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in list prices, net prices, and discounts of self-administered injectable tumor necrosis factor inhibitors.
    San-Juan-Rodriguez A; Piro VM; Good CB; Gellad WF; Hernandez I
    J Manag Care Spec Pharm; 2021 Jan; 27(1):112-117. PubMed ID: 33377437
    [No Abstract]   [Full Text] [Related]  

  • 3. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
    Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
    JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
    Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
    JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?
    Mattingly TJ; Levy JF; Slejko JF; Onwudiwe NC; Perfetto EM
    Pharmacoeconomics; 2018 Sep; 36(9):1093-1099. PubMed ID: 29752675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018.
    Lakdawalla D; Li M
    JAMA Netw Open; 2021 May; 4(5):e219030. PubMed ID: 33950205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated Changes in Insulin Prices and Discounts After Entry of New Insulin Products, 2012-2019.
    Dickson S; Gabriel N; Gellad WF; Hernandez I
    JAMA Health Forum; 2023 Jun; 4(6):e231430. PubMed ID: 37327008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Commercial and Mandatory Discounts in the Gross-to-Net Bubble for the Top Insulin Products From 2012 to 2019.
    Dickson SR; Gabriel N; Gellad WF; Hernandez I
    JAMA Netw Open; 2023 Jun; 6(6):e2318145. PubMed ID: 37314806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
    Yeung K; Dusetzina SB; Basu A
    JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies.
    Kakani P; Chernew M; Chandra A
    J Health Polit Policy Law; 2022 Dec; 47(6):629-648. PubMed ID: 35867538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives.
    Hernandez I; Cousin EM; Wouters OJ; Gabriel N; Cameron T; Sullivan SD
    J Manag Care Spec Pharm; 2024 Aug; 30(8):762-772. PubMed ID: 38905356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Net prices of new antiobesity medications.
    Hernandez I; Sullivan SD
    Obesity (Silver Spring); 2024 Mar; 32(3):472-475. PubMed ID: 38228492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
    Rome BN; Feldman WB; Desai RJ; Kesselheim AS
    JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear.
    Sarpatwari A; Tessema FA; Zakarian M; Najafzadeh MN; Kesselheim AS
    Health Aff (Millwood); 2021 May; 40(5):772-778. PubMed ID: 33939506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
    Wineinger NE; Zhang Y; Topol EJ
    JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
    Berkemeier F; Whaley C; Robinson JC
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
    Hayford TB
    JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Branded Price Variation in the United States Drug Market, 2010 to 2019.
    Levy J; Ippolito B
    Value Health; 2021 Sep; 24(9):1237-1240. PubMed ID: 34452701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.